Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
Blood Advances|December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxAlex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology|February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groupsAlex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
Blood Advances|December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxAlex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology|February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groupsAlex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Pageof 16